| Today’s Big NewsMar 21, 2024 |
| By Zoey Becker Idorsia's Tryvio is the first oral anti-hypertensive therapy that uses a new therapeutic mechanism in nearly 40 years, suggesting the dawn of "a new era of endothelin research," the company said. |
|
|
|
By James Waldron Boundless Bio’s announcement earlier this month of plans to go public was a sign that the biotech IPO window hadn’t slammed shut after a flurry of offerings at the start of the year. |
By Andrea Park If the proposed stateside ban of TikTok is enacted, the U.S. will have to bid adieu to the app’s seemingly never-ending roster of viral dances and meme trends, its knack for extremely niche community-building and, for corporate users, a particularly captive audience for company messaging. |
By Conor Hale The recall, spanning 66,000 Impella pumps in the U.S., has been tied to 49 deaths among 129 severe injuries where the device pierced the heart wall, according to the FDA. |
|
Wednesday, March 27, 2024 | 10am ET / 7am PTThere can be numerous challenges encountered during biopharmaceutical process development. Join usfor an important look at formulation development specifically. Featuring real-world examples, this insightful discussion will explore key challenges, as well as the latest techniques and solutions for effectively overcoming current obstacles. Register now.
|
|
By Fraiser Kansteiner Despite a multi-billion-dollar takeover bid from Novo Holdings, contract manufacturer Catalent appears to be continuing with the internal restructuring scheme it unveiled last year. For more than a hundred of the CDMO’s employees in the United States, that means new job cuts are on the table. |
By James Waldron Just two months after the FDA lifted a clinical hold on trials of Innate Pharma’s lymphoma drug, the biotech has now dropped plans to pursue the anti-KIR3DL2 antibody as a monotherapy for a specific form of that cancer. |
By Conor Hale In a livestream on X, Neuralink user Noland Arbaugh said a diving accident had dislocated the vertebrae in his neck, leaving him paralyzed from the shoulders down. After receiving the Neuralink implant, Arbaugh said he could now easily move the chess pieces around his laptop screen while also using the digital connection to control its music player. |
By Kevin Dunleavy In his final year as CEO at Bristol Myers Squibb, Giovanni Caforio took a slight dip in pay to $19.7 million, down from the $20.1 million he collected in 2022. |
By Nick Paul Taylor AstraZeneca wants to turn a challenge into a strength. Facing the need to change 50 years of prescribing habits in asthma, the drugmaker is running a TV ad that presents the incumbent as a dinosaur, literally, and makes the case for switching to the new rescue inhaler Airsupra. |
By Fraiser Kansteiner A little less than a year after Merck KGaA unveiled designs on a new bioprocessing plant in South Korea, the company’s U.S.- and Canada-based life sciences business, MilliporeSigma, has swooped in with a hefty investment at the site and the promise of hundreds of new jobs. |
By Annalee Armstrong A brand-new biotech called Mirador Therapeutics has emerged from the team behind Prometheus Biosciences with a massive $400 million series A funding round—the biggest of 2024 so far. |
By Ben Adams Amid Colorectal Cancer (CRC) Awareness Month this March, analysts at GlobalData are warning that health bodies around the world need to “reevaluate CRC screening programs” while boosting awareness around the disease. |
By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Kevin Dunleavy,Zoey Becker In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
By Nick Paul Taylor BioTek reMEDys has identified Bleeding Disorders Awareness Month (BDAM) as an opportunity to drive change, piggybacking on the national event to call for awareness of safe medication use in patients with the conditions. |
Fierce podcastsDon’t miss an episode |
| | In this episode of 'The Top Line,' Fierce Biotech Senior Editor Annalee Armstrong interviews Karen Correa, Ph.D., from Takeda, discussing the crucial need for pharmaceutical companies to prioritize diversity in clinical trials. |
|
|---|
|
|
|
Monday, April 22, 2024 | 10am ET / 7am PTExplore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now!
|
|
| WhitepaperExplore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
| Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
